Uploaded August 2026 | Updated September 2026, 2 weeks ago
Beth Wiese presents "Cannabidiol to Mitigate Opioid Induced Respiratory Depression" at CannMed 2026, covering CBD respiratory depression, opioid overdose prevention, and cannabidiol research.
Opioids continue to be the cause of a US public health emergency, accounting for more than 1,000,000 overdose fatalities since 1999, but are unrivaled in their analgesic efficacy. Cannabidiol (CBD), a non-psychoactive cannabinoid that does not alter breathing on its own, has mitigated morphine and fentanyl induced respiratory depression in mice. In this study, we investigated CBD vaping effects on breathing following opioid administration of methadone and hydrocodone in opioid-dependent human subjects.
Respiratory recordings using bluetooth enabled respiration belts were utilized to collect breathing behavior from human subjects for 10 minutes before and after oral methadone or hydrocodone consumption, and 20 minutes following 2-3 puffs of CBD inhalation at 10mg per puff. Data on baseline breathing behavior was gathered prior to opioid and CBD consumption to obtain pre-post outcome data on respiratory depressive effects.
Breathing behavior following methadone or hydrocodone consumption shows no difference in depth of respiratory depression. Following CBD inhalation of 20mg or 30mg, breathing behavior returned to baseline levels.
Learning Objectives:
⦿ CBD vaping was effective at returning opioid-induced respiratory depressive effects of two regulated opioids back to baseline levels
⦿ CBD vaping may be a novel prevention to fatal overdose from opioids
Beth Wiese, PhD is the Research and Overdose Prevention Coordinator at The Sidewalk Project.
This presentation was given at the CannMed 2026 Innovation & Collaboration Summit, held June 15-18 at the Hyatt Regency Lake Tahoe Resort. Visit cannmedevents.com to learn more.
Beth Wiese presents "Cannabidiol to Mitigate Opioid Induced Respiratory Depression" at CannMed 2026, covering CBD respiratory depression, opioid overdose prevention, and cannabidiol research.
Opioids continue to be the cause of a US public health emergency, accounting for more than 1,000,000 overdose fatalities since 1999, but are unrivaled in their analgesic efficacy. Cannabidiol (CBD), a non-psychoactive cannabinoid that does not alter breathing on its own, has mitigated morphine and fentanyl induced respiratory depression in mice. In this study, we investigated CBD vaping effects on breathing following opioid administration of methadone and hydrocodone in opioid-dependent human subjects.
Respiratory recordings using bluetooth enabled respiration belts were utilized to collect breathing behavior from human subjects for 10 minutes before and after oral methadone or hydrocodone consumption, and 20 minutes following 2-3 puffs of CBD inhalation at 10mg per puff. Data on baseline breathing behavior was gathered prior to opioid and CBD consumption to obtain pre-post outcome data on respiratory depressive effects.
Breathing behavior following methadone or hydrocodone consumption shows no difference in depth of respiratory depression. Following CBD inhalation of 20mg or 30mg, breathing behavior returned to baseline levels.
Learning Objectives:
⦿ CBD vaping was effective at returning opioid-induced respiratory depressive effects of two regulated opioids back to baseline levels
⦿ CBD vaping may be a novel prevention to fatal overdose from opioids
Beth Wiese, PhD is the Research and Overdose Prevention Coordinator at The Sidewalk Project.
This presentation was given at the CannMed 2026 Innovation & Collaboration Summit, held June 15-18 at the Hyatt Regency Lake Tahoe Resort. Visit cannmedevents.com to learn more.
